Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. (NASDAQ: CODX) is a molecular diagnostics innovator developing PCR-based testing solutions through its patented Co-Primers™ technology. This page serves as the definitive source for verified company news and announcements, providing stakeholders with timely updates on developments impacting global healthcare diagnostics.
Investors and industry professionals will find curated press releases covering financial results, regulatory milestones, product launches, and strategic partnerships. Our aggregation includes updates on CODX's expanding test menu (including tuberculosis and respiratory disease diagnostics), manufacturing expansions, and progress toward decentralized testing solutions through the Co-Dx™ platform.
Key resources include earnings call transcripts, FDA clearance announcements, and analysis of emerging market initiatives like the CoSara Diagnostics joint venture in India. All content is organized chronologically demonstrate the company's trajectory while maintaining compliance with financial disclosure standards.
Bookmark this page for direct access to primary source materials that inform investment decisions and industry analysis. Check regularly for updates on CODX's contributions to accessible, high-accuracy diagnostic testing worldwide.
Co-Diagnostics (Nasdaq-CM: CODX) has announced its participation at the Association for Molecular Pathology (AMP) annual expo in Phoenix, AZ, from November 1-5. The event is a key gathering for molecular diagnostics professionals. Visitors can explore Co-Diagnostics' pioneering CoPrimer™ PCR technology and infectious disease products at booth #712. The expo starts at 12 pm PT on November 3. For further details, registration information is available here.
Co-Diagnostics, Inc. (Nasdaq: CODX) has appointed Dr. Mark Poritz as the new Chief Scientific Officer. Dr. Poritz is a seasoned molecular biologist with over 30 years of experience in molecular diagnostics, notably at BioFire Diagnostics. He has previously led significant developments, including the FilmArray platform. His appointment comes with an emphasis on enhancing the accessibility of innovative diagnostic solutions. The company also expresses gratitude to outgoing CSO Dr. Jesse Montgomery for his contributions.
Co-Diagnostics, Inc. (Nasdaq: CODX) will announce its third quarter 2022 results on November 10, 2022, after market close. The company will also host a conference call and webcast at 4:30 p.m. EDT to discuss financial outcomes with analysts and investors. Key management present will include CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson. The event will be accessible via the company's website, with a recorded version available later for those unable to attend live.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) will host a booth at Africa Health/Medlab Africa in Johannesburg, South Africa from October 26-28, 2022. This significant event brings together healthcare professionals from the South African Development Community and beyond, showcasing the latest in medical technology and services. Co-Diagnostics will present their innovative CoPrimer™ PCR technology and infectious disease products, alongside the upcoming Co-Dx PCR Home testing platform. Attendees can find registration details here.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced its participation in IDWeek 2022 in Washington, D.C. from October 19-23 and Asia Health/Medlab Asia in Bangkok, Thailand from October 19-21. These conferences aim to update professionals on infectious diseases and connect healthcare communities. Co-Diagnostics will showcase its CoPrimer™ PCR technology and upcoming Co-Dx PCR Home testing platform at both events. Attendees can find more information on registration at the respective conference websites.
Co-Diagnostics (Nasdaq-CM: CODX) is sponsoring and hosting a booth at the Caribbean Public Health Agency's 66th Annual Health Research Conference on September 15-17 in Jamaica. The theme this year is 'COVID-19 and Digital Health: Transforming, Connecting, Informing Public Health.' Co-Dx will showcase its infectious disease and vector control products, along with the upcoming Co-Dx PCR Home testing platform. The company's presentation is scheduled for September 16 at 10:15 am local time.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced its participation in the H.C. Wainwright & Co. 24th Annual Global Investment Conference from September 12-14, 2022, in New York City. CEO Dwight Egan will present on the company’s progress and upcoming Co-Dx PCR Home Diagnostic Platform. The presentation is scheduled for September 13 at 8:30 AM ET, accessible for registered institutional investors. One-on-one meetings with H.C. Wainwright representatives will also be available.
SALT LAKE CITY, Aug. 31, 2022 /PRNewswire/ -- Co-Diagnostics (Nasdaq: CODX) will showcase its innovative molecular diagnostics at Medical Fair Asia 2022 from August 31 to September 2 in Singapore. This premier medical trade fair is expected to attract over 14,000 visitors from 70 countries, offering Co-Dx an opportunity to strengthen its distributor outreach and connect with international customers. Attendees can learn more about Co-Diagnostics’ products, including its point-of-care PCR diagnostics, at Booth #2G01.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) is set to sponsor, present, and host a booth at the 14th Annual Next Generation Dx Summit from August 22-24 in Washington, D.C.. The summit focuses on advancements in point-of-care, infectious disease, and liquid biopsy diagnostics. CEO Dwight Egan will present the upcoming Co-Dx PCR Home platform on August 22 at 12:15 PM ET. In-person attendees can visit the Company at Booth #206. For more details on the summit, visit Next Generation Dx.
Co-Diagnostics, Inc. (NASDAQ: CODX) released its second quarter 2022 financial results, reporting a revenue decline to $5.0 million from $27.4 million year-over-year, primarily due to decreased demand for its Logix Smart™ COVID-19 Test. The company faced an operating loss of $4.1 million, contrasting with a prior year operating income of $11.8 million. Net loss registered at $2.7 million, or $0.08 per share. Despite these challenges, Co-Diagnostics continues to progress on the Co-Dx PCR Home platform and expand its product offerings, including tests for monkeypox.
